Bladder Cancer

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

Data from the phase 3b study were recently published in Reviews in Urology, showing that administration of mitomycin intravesical solution in the home setting was feasible, safe, and effective.

Ultimately, the take-home message for practicing urologists is to apply TMT judiciously, taking into account the patient's clinical profile, personal values, and financial situation.

Betty Wang, MD, said she envisions ctDNA integrating into existing surveillance protocols for patients with high-risk NMIBC.

Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.

Take a look back through some of the top stories from the first half of the year.

The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.

The Continuity Grant will support projects in bladder cancer and/or upper tract urothelial carcinoma that were previously scientifically reviewed, approved, and funded.

Alpha1H was granted a fast track designation in November 2023.

Wang and Bukavina outline several cases of ctDNA's utility in the space.

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.

According to Daniel D. Joyce, MD, MS, policy initiatives should focus on improving the value and efficiency of radiation.

According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.

The data, collected as part of the phase 1/2 Duravelo-1 trial, showed an objective response rate of 65%.

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

Findings indicated that although trimodal therapy improved the quality of life for patients with muscle-invasive bladder cancer compared with cystectomy, its significantly higher cost made it not cost-effective.

Take a look through all the regulatory milestones in urology from the first half of the 2025.

A notable finding was that 35% of these NMIBC patients exhibited ctDNA positivity.

Catch up on exclusive videos you may have missed from the first half of the year.

Here’s a look back at notable news between April and June 2025.

In this video, part 5 in a 5-part series, panelists examine the economic and logistical realities of bringing mitomycin for intravesical solution (Zusduri; formerly UGN-102) into private practice.

In this video, part 4 in a 5-part series, Nick Liu, MD, outlines key scenarios where surgical resection remains preferred for treating LG-IR-NMIBC.

In this video, part 3 in a 5-part series, panelists discuss the long-term clinical impact and health care system implications of mitomycin for intravesical solution (Zusduri; formerly UGN-102).

In this video, part 2 in a 5-part series, Nick Liu, MD, breaks down the formulation behind mitomycin for intravesical solution (Zusduri; formerly UGN-102).